Compound Monoammonium Glycyrrhizinate Injection

Glycyrrhizic acid monoamine has a strong affinity for steroid metabolic enzymes in the liver, thereby hindering the inactivation of cortisol and aldosterone. After use, it shows obvious corticosteroid-like effects, such as anti-inflammatory effects, anti-allergic effects, and protective membrane structures; there are no obvious corticosteroid-like adverse reactions. This product can promote monochrome metabolism, reduce the release of ALT and AST; induce γ-IFN and interleukin II, increase NK cell activity and OKT4/OKT8 ratio and activate the reticuloendothelial system; inhibit mast cell release of histamine; inhibit the formation of cell membrane phospholipase A2 (PL-A2) and prostaglandin E2 (PGE2) and granulomatous reactions; inhibit the production and formation of free radicals and lipid peroxides, and reduce the activity of proline hydroxylase; regulate calcium ion channels, protect lysosomal membranes and mitochondria

This product is a compound preparation, and its components are: each 1 ml contains 2 mg of monoammonium glycyrrhizinate (C42H65NO16·2H2O), 1.5 mg of L-cysteine hydrochloride (C3H7NO2S·HCl·H2O), and 20 mg of glycine (C2H5NO2).

This product is a colorless clear liquid.

It is used for abnormal liver function caused by acute and chronic hepatitis; it has a certain auxiliary therapeutic effect on toxic hepatitis. It can also be used for food poisoning, drug poisoning, drug allergy, etc.

Intravenous drip. 20-80 ml at a time, add 5% glucose or 0.9% sodium chloride 250-500 ml injection solution to dilute, and slowly drip. Once a day. Intravenous injection. 20-80 ml at a time, add an equal amount of 5% glucose injection solution, and slowly push intravenously. Once a day.

Poor appetite, nausea, vomiting, abdominal distension, as well as itchy skin, urticaria, dry mouth and edema; common cardiovascular and cerebrovascular system symptoms include headache, dizziness, palpitations and increased blood pressure. The above symptoms are generally mild and do not affect treatment.

1. Patients who are allergic to this product are prohibited from using this product. 2. Patients with severe hypokalemia and hypernatremia are prohibited from using this product. 3. Patients with hypertension and heart failure are prohibited from using this product. 4. Patients with renal failure are prohibited from using this product. 5. Patients with aldosteronism and tumors are prohibited from using this product.

Hypokalemia is likely to occur when used in combination with furosemide (Lasix) or thiazide diuretics.

Keep tightly closed in a cool, dark place.

20ml per bottle

Changshu Leiyunshang Pharmaceutical Co., Ltd.

• Founded in:

  1998-10-09

• Address:

  No. 90 Shenzhen Road, Changshu City, Suzhou

• Tax NO.:

  913205817036728233

• Registered Funds:

  53.2 million yuan

• Website:

  Log in to view

• Email:

  Log in to view